Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gecacitinib for anemia in MDS and MDS/MPN with myelofibrosis
ChiCTR2500113178Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of jaktinib in myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), myelofibrosis (MF) and 1 more (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of subjects achieving erythroid response (HI-E or protocol-defined erythroid response). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
jaktinib
03
Conditions
myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)myelofibrosis (MF)anaemia
Beyond the preview
Go deeper on ChiCTR2500113178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113178.